{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T03:38:23Z","timestamp":1782445103745,"version":"3.54.5"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2021,7,10]],"date-time":"2021-07-10T00:00:00Z","timestamp":1625875200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,7,10]],"date-time":"2021-07-10T00:00:00Z","timestamp":1625875200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1007\/s00228-021-03179-w","type":"journal-article","created":{"date-parts":[[2021,7,10]],"date-time":"2021-07-10T15:02:22Z","timestamp":1625929342000},"page":"1861-1873","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Population pharmacokinetics and exposure\u2013response relationship of trastuzumab and bevacizumab in early-stage breast cancer"],"prefix":"10.1007","volume":"77","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4811-0439","authenticated-orcid":false,"given":"A.","family":"Petitcollin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Azzopardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Y.","family":"Pierga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Ternant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Navarro-Teulon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Desvignes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. A.","family":"Mouret-Reynier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Coudert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Paintaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,10]]},"reference":[{"key":"3179_CR1","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1016\/j.ejca.2012.12.027","volume":"49","author":"J Ferlay","year":"2013","unstructured":"Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, Forman D, Bray F (2013) Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 49:1374\u20131403","journal-title":"Eur J Cancer"},{"key":"3179_CR2","first-page":"944","volume":"51","author":"GM Clark","year":"1991","unstructured":"Clark GM, McGuire WL (1991) Follow-up study of HER-2\/neu amplification in primary breast cancer. Cancer Res 51:944\u2013948","journal-title":"Cancer Res"},{"key":"3179_CR3","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1093\/annonc\/mdn369","volume":"19","author":"S Menard","year":"2008","unstructured":"Menard S, Balsari A, Tagliabue E, Camerini T, Casalini P, Bufalino R, Castiglioni F, Carcangiu ML, Gloghini A, Scalone S, Querzoli P, Lunardi M, Molino A, Mandara M, Mottolese M, Marandino F, Venturini M, Bighin C, Cancello G, Montagna E, Perrone F, De Matteis A, Sapino A, Donadio M, Battelli N, Santinelli A, Pavesi L, Lanza A, Zito FA, Labriola A, Aiello RA, Caruso M, Zanconati F, Mustacchi G, Barbareschi M, Frisinghelli M, Russo R, Carrillo G, Group O (2008) Biology, prognosis and response to therapy of breast carcinomas according to HER2 score. Ann Oncol 19:1706\u20131712","journal-title":"Ann Oncol"},{"key":"3179_CR4","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1093\/annonc\/mdj096","volume":"17","author":"BP Coudert","year":"2006","unstructured":"Coudert BP, Arnould L, Moreau L, Chollet P, Weber B, Vanlemmens L, Molucon C, Tubiana N, Causeret S, Misset JL, Feutray S, Mery-Mignard D, Garnier J, Fumoleau P (2006) Pre-operative systemic (neo-adjuvant) therapy with trastuzumab and docetaxel for HER2-overexpressing stage II or III breast cancer: results of a multicenter phase II trial. Ann Oncol 17:409\u2013414","journal-title":"Ann Oncol"},{"key":"3179_CR5","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/BF02968293","volume":"11","author":"M Kurosumi","year":"2004","unstructured":"Kurosumi M (2004) Significance of histopathological evaluation in primary therapy for breast cancer\u2013recent trends in primary modality with pathological complete response (pCR) as endpoint. Breast Cancer 11:139\u2013147","journal-title":"Breast Cancer"},{"key":"3179_CR6","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1097\/CCO.0b013e32835ff362","volume":"25","author":"RS Alameddine","year":"2013","unstructured":"Alameddine RS, Otrock ZK, Awada A, Shamseddine A (2013) Crosstalk between HER2 signaling and angiogenesis in breast cancer: molecular basis, clinical applications and challenges. Curr Opin Oncol 25:313\u2013324","journal-title":"Curr Opin Oncol"},{"key":"3179_CR7","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1016\/S1470-2045(14)70475-9","volume":"15","author":"B Coudert","year":"2014","unstructured":"Coudert B, Pierga JY, Mouret-Reynier MA, Kerrou K, Ferrero JM, Petit T, Kerbrat P, Dupre PF, Bachelot T, Gabelle P, Giard S, Coeffic D, Bougnoux P, Prevost JB, Paintaud G, Thibault G, Hernandez J, Coudert M, Arnould L, Berriolo-Riedinger A (2014) Use of [(18)F]-FDG PET to predict response to neoadjuvant trastuzumab and docetaxel in patients with HER2-positive breast cancer, and addition of bevacizumab to neoadjuvant trastuzumab and docetaxel in [(18)F]-FDG PET-predicted non-responders (AVATAXHER): an open-label, randomised phase 2 trial. Lancet Oncol 15:1493\u20131502","journal-title":"Lancet Oncol"},{"key":"3179_CR8","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/s00280-005-1026-z","volume":"56","author":"R Bruno","year":"2005","unstructured":"Bruno R, Washington CB, Lu JF, Lieberman G, Banken L, Klein P (2005) Population pharmacokinetics of trastuzumab in patients with HER2+ metastatic breast cancer. Cancer Chemother Pharmacol 56:361\u2013369","journal-title":"Cancer Chemother Pharmacol"},{"key":"3179_CR9","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1007\/s00280-014-2400-5","volume":"73","author":"VF Cosson","year":"2014","unstructured":"Cosson VF, Ng VW, Lehle M, Lum BL (2014) Population pharmacokinetics and exposure-response analyses of trastuzumab in patients with advanced gastric or gastroesophageal junction cancer. Cancer Chemother Pharmacol 73:737\u2013747","journal-title":"Cancer Chemother Pharmacol"},{"key":"3179_CR10","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1111\/bcp.12875","volume":"81","author":"G Bernadou","year":"2016","unstructured":"Bernadou G, Campone M, Merlin JL, Gouilleux-Gruart V, Bachelot T, Lokiec F, Rezai K, Arnedos M, Dieras V, Jimenez M, Paintaud G, Ternant D (2016) Influence of tumour burden on trastuzumab pharmacokinetics in HER2 positive non-metastatic breast cancer. Br J Clin Pharmacol 81:941\u2013948","journal-title":"Br J Clin Pharmacol"},{"key":"3179_CR11","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/s00280-018-3728-z","volume":"83","author":"AL Quartino","year":"2019","unstructured":"Quartino AL, Li H, Kirschbrown WP, Mangat R, Wada DR, Garg A, Jin JY, Lum B (2019) Population pharmacokinetic and covariate analyses of intravenous trastuzumab (Herceptin((R))), a HER2-targeted monoclonal antibody, in patients with a variety of solid tumors. Cancer Chemother Pharmacol 83:329\u2013340","journal-title":"Cancer Chemother Pharmacol"},{"issue":"Suppl 1","key":"3179_CR12","doi-asserted-by":"publisher","first-page":"S49","DOI":"10.1093\/annonc\/12.suppl_1.S49","volume":"12","author":"J Baselga","year":"2001","unstructured":"Baselga J (2001) Phase I and II clinical trials of trastuzumab. Ann Oncol 12(Suppl 1):S49-55","journal-title":"Ann Oncol"},{"key":"3179_CR13","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1007\/s00280-007-0664-8","volume":"62","author":"JF Lu","year":"2008","unstructured":"Lu JF, Bruno R, Eppler S, Novotny W, Lum B, Gaudreault J (2008) Clinical pharmacokinetics of bevacizumab in patients with solid tumors. Cancer Chemother Pharmacol 62:779\u2013786","journal-title":"Cancer Chemother Pharmacol"},{"key":"3179_CR14","doi-asserted-by":"publisher","first-page":"7147","DOI":"10.1158\/0008-5472.CAN-13-2532","volume":"73","author":"M Arjaans","year":"2013","unstructured":"Arjaans M, Oosting SF, Schroder CP, de Vries EG (2013) Bevacizumab-induced vessel normalization hampers tumor uptake of antibodies\u2013response. Cancer Res 73:7147\u20137148","journal-title":"Cancer Res"},{"key":"3179_CR15","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1158\/1535-7163.MCT-11-0742-T","volume":"11","author":"CV Pastuskovas","year":"2012","unstructured":"Pastuskovas CV, Mundo EE, Williams SP, Nayak TK, Ho J, Ulufatu S, Clark S, Ross S, Cheng E, Parsons-Reponte K, Cain G, Van Hoy M, Majidy N, Bheddah S, dela Cruz Chuh J, Kozak KR, Lewin-Koh N, Nauka P, Bumbaca D, Sliwkowski M, Tibbitts J, Theil FP, Fielder PJ, Khawli LA, Boswell CA (2012) Effects of anti-VEGF on pharmacokinetics, biodistribution, and tumor penetration of trastuzumab in a preclinical breast cancer model. Mol Cancer Ther 11:752\u2013762","journal-title":"Mol Cancer Ther"},{"key":"3179_CR16","doi-asserted-by":"publisher","first-page":"63","DOI":"10.2967\/jnumed.114.144840","volume":"56","author":"SF Oosting","year":"2015","unstructured":"Oosting SF, Brouwers AH, van Es SC, Nagengast WB, Oude Munnink TH, Lub-de Hooge MN, Hollema H, de Jong JR, de Jong IJ, de Haas S, Scherer SJ, Sluiter WJ, Dierckx RA, Bongaerts AH, Gietema JA, de Vries EG (2015) 89Zr-bevacizumab PET visualizes heterogeneous tracer accumulation in tumor lesions of renal cell carcinoma patients and differential effects of antiangiogenic treatment. J Nucl Med 56:63\u201369","journal-title":"J Nucl Med"},{"key":"3179_CR17","doi-asserted-by":"crossref","unstructured":"Chevallier B, Roche H, Olivier JP, Chollet P, Hurteloup P (1993) Inflammatory breast cancer. Pilot study of intensive induction chemotherapy (FEC-HD) results in a high histologic response rate. Am J Clin Oncol\u00a016:223\u2013228","DOI":"10.1097\/00000421-199306000-00006"},{"key":"3179_CR18","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1097\/FTD.0b013e3181ef582a","volume":"32","author":"D Ternant","year":"2010","unstructured":"Ternant D, Ceze N, Lecomte T, Degenne D, Duveau AC, Watier H, Dorval E, Paintaud G (2010) An enzyme-linked immunosorbent assay to study bevacizumab pharmacokinetics. Ther Drug Monit 32:647\u2013652","journal-title":"Ther Drug Monit"},{"key":"3179_CR19","doi-asserted-by":"crossref","unstructured":"Bernadou G CM, Merlin J-L, Gouilleux-Gruart V, Lokiec F, Rezai K, Delaloge S, Di\u00e9ras V, Jimenez M, Paintaud G, Ternant D (2015) Influence of tumour burden on trastuzumab pharmacokinetics in HER2 positive non-metastatic breast cancer. Submitted","DOI":"10.1111\/bcp.12875"},{"key":"3179_CR20","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.cmpb.2007.12.002","volume":"90","author":"E Comets","year":"2008","unstructured":"Comets E, Brendel K, Mentre F (2008) Computing normalised prediction distribution errors to evaluate nonlinear mixed-effect models: the npde add-on package for R. Comput Methods Prog Biomed 90:154\u2013166","journal-title":"Comput Methods Prog Biomed"},{"key":"3179_CR21","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1007\/s00228-016-2101-6","volume":"72","author":"JA Reijers","year":"2016","unstructured":"Reijers JA, van Donge T, Schepers FM, Burggraaf J, Stevens J (2016) Use of population approach non-linear mixed effects models in the evaluation of biosimilarity of monoclonal antibodies. Eur J Clin Pharmacol 72:1343\u20131352","journal-title":"Eur J Clin Pharmacol"},{"key":"3179_CR22","doi-asserted-by":"publisher","first-page":"3003","DOI":"10.1200\/JCO.2004.11.061","volume":"22","author":"EK Rowinsky","year":"2004","unstructured":"Rowinsky EK, Schwartz GH, Gollob JA, Thompson JA, Vogelzang NJ, Figlin R, Bukowski R, Haas N, Lockbaum P, Li YP, Arends R, Foon KA, Schwab G, Dutcher J (2004) Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer. J Clin Oncol 22:3003\u20133015","journal-title":"J Clin Oncol"},{"key":"3179_CR23","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1177\/0091270007313393","volume":"48","author":"NL Dirks","year":"2008","unstructured":"Dirks NL, Nolting A, Kovar A, Meibohm B (2008) Population pharmacokinetics of cetuximab in patients with squamous cell carcinoma of the head and neck. J Clin Pharmacol 48:267\u2013278","journal-title":"J Clin Pharmacol"},{"key":"3179_CR24","doi-asserted-by":"publisher","first-page":"6329","DOI":"10.1158\/1078-0432.CCR-11-1081","volume":"17","author":"N Azzopardi","year":"2011","unstructured":"Azzopardi N, Lecomte T, Ternant D, Boisdron-Celle M, Piller F, Morel A, Gouilleux-Gruart V, Vignault-Desvignes C, Watier H, Gamelin E, Paintaud G (2011) Cetuximab pharmacokinetics influences progression-free survival of metastatic colorectal cancer patients. Clin Cancer Res 17:6329\u20136337","journal-title":"Clin Cancer Res"},{"key":"3179_CR25","doi-asserted-by":"crossref","unstructured":"Petitcollin A, Bensalem A, Verdier MC, Tron C, Lemaitre F, Paintaud G, Bellissant E, Ternant D (2019) Modelling of the time-varying pharmacokinetics of therapeutic monoclonal antibodies: a literature review. Clin Pharmacokinet","DOI":"10.1007\/s40262-019-00816-7"},{"key":"3179_CR26","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1111\/bcp.13270","volume":"83","author":"B Lioger","year":"2017","unstructured":"Lioger B, Edupuganti SR, Mulleman D, Passot C, Desvignes C, Bejan-Angoulvant T, Thibault G, Gouilleux-Gruart V, Melet J, Paintaud G, Ternant D (2017) Antigenic burden and serum IgG concentrations influence rituximab pharmacokinetics in rheumatoid arthritis patients. Br J Clin Pharmacol 83:1773\u20131781","journal-title":"Br J Clin Pharmacol"},{"key":"3179_CR27","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1136\/ard.2009.109041","volume":"69","author":"RM Thurlings","year":"2010","unstructured":"Thurlings RM, Teng O, Vos K, Gerlag DM, Aarden L, Stapel SO, van Laar JM, Tak PP, Wolbink GJ (2010) Clinical response, pharmacokinetics, development of human anti-chimaeric antibodies, and synovial tissue response to rituximab treatment in patients with rheumatoid arthritis. Ann Rheum Dis 69:409\u2013412","journal-title":"Ann Rheum Dis"},{"key":"3179_CR28","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s00280-012-2031-7","volume":"71","author":"J Li","year":"2013","unstructured":"Li J, Gupta M, Jin D, Xin Y, Visich J, Allison DE (2013) Characterization of the long-term pharmacokinetics of bevacizumab following last dose in patients with resected stage II and III carcinoma of the colon. Cancer Chemother Pharmacol 71:575\u2013580","journal-title":"Cancer Chemother Pharmacol"},{"key":"3179_CR29","doi-asserted-by":"crossref","unstructured":"Panoilia E, Schindler E, Samantas E, Aravantinos G, Kalofonos HP, Christodoulou C, Patrinos GP, Friberg LE, Sivolapenko G (2015) A pharmacokinetic binding model for bevacizumab and VEGF in colorectal cancer patients. Cancer Chemother Pharmacol","DOI":"10.1007\/s00280-015-2701-3"},{"key":"3179_CR30","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1200\/JCO.2001.19.3.843","volume":"19","author":"MS Gordon","year":"2001","unstructured":"Gordon MS, Margolin K, Talpaz M, Sledge GW Jr, Holmgren E, Benjamin R, Stalter S, Shak S, Adelman D (2001) Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 19:843\u2013850","journal-title":"J Clin Oncol"},{"key":"3179_CR31","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1007\/s40262-016-0406-3","volume":"55","author":"M Caulet","year":"2016","unstructured":"Caulet M, Lecomte T, Bouche O, Rollin J, Gouilleux-Gruart V, Azzopardi N, Leger J, Borg C, Douillard JY, Manfredi S, Smith D, Capitain O, Ferru A, Moussata D, Terrebone E, Paintaud G, Ternant D (2016) Bevacizumab Pharmacokinetics Influence Overall and Progression-Free Survival in Metastatic Colorectal Cancer Patients. Clin Pharmacokinet 55:1381\u20131394","journal-title":"Clin Pharmacokinet"},{"key":"3179_CR32","doi-asserted-by":"publisher","first-page":"2616","DOI":"10.1182\/blood-2016-10-744292","volume":"129","author":"M Tout","year":"2017","unstructured":"Tout M, Casasnovas O, Meignan M, Lamy T, Morschhauser F, Salles G, Gyan E, Haioun C, Mercier M, Feugier P, Boussetta S, Paintaud G, Ternant D, Cartron G (2017) Rituximab exposure is influenced by baseline metabolic tumor volume and predicts outcome of DLBCL patients: a Lymphoma Study Association report. Blood 129:2616\u20132623","journal-title":"Blood"},{"key":"3179_CR33","doi-asserted-by":"crossref","unstructured":"Arjaans M, Munnink THO, Oosting SF, van Scheltinga AGT, Gietema JA, Garbacik ET, Timmer-Bosscha H, Lub-de Hooge MN, Schroder CP, de Vries EG (2013) Bevacizumab-induced normalization of blood vessels in tumors hampers antibody uptake. Cancer Res\u00a073:3347\u20133355","DOI":"10.1158\/0008-5472.CAN-12-3518"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-021-03179-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-021-03179-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-021-03179-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,11]],"date-time":"2021-11-11T06:03:21Z","timestamp":1636610601000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-021-03179-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,10]]},"references-count":33,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["3179"],"URL":"https:\/\/doi.org\/10.1007\/s00228-021-03179-w","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,10]]},"assertion":[{"value":"20 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study approval was obtained from the central Ethics Committee (Comit\u00e9 de Protection des Personnes) in all of the participating centres. The trial was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All patients provided written informed consent for their participation to the AvaTaxHer clinical trial, and specific consent was obtained for participating to the pharmacokinetic study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All authors have completed the Unified Competing Interest form. Dr. Pierga reports grants from Roche, during the conduct of the study; personal fees from Novartis, personal fees from Puma, grants and non-financial support from MSD, grants and personal fees from Roche, personal fees and non-financial support from Genomic Health, personal fees from Lilly, personal fees from Astra Zeneca, personal fees from Amgen, personal fees from Pfizer, outside the submitted work. Dr. Coudert reports personal fees and non-financial support from Roche Laboratories France, during the conduct of the study. Dr. Ternant reports grants from Amgen, grants from Boerhinger Ingelheim, outside the submitted work. Dr. Paintaud reports grants from Roche Pharma, during the conduct of the study; grants from Novartis, grants from Roche Pharma, grants from Sanofi-Genzyme, grants from Chugai, grants from Pfizer, outside the submitted work. All the other authors declare no support from any organisation for the submitted work.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}